Literature DB >> 16139121

Long-term results (three to five years) of the Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study.

Fernando Alfonso1, José M Augé, Javier Zueco, Armando Bethencourt, José R López-Mínguez, José M Hernández, Juan A Bullones, Isabel Calvo, Enrique Esplugas, María J Pérez-Vizcayno, Raul Moreno, Cristina Fernández, Rosana Hernández, Vasco Gama-Ribeiro.   

Abstract

OBJECTIVES: We sought to analyze the very late outcomes of patients treated for in-stent restenosis (ISR) according to treatment allocation and 10 prespecified variables.
BACKGROUND: Long-term results (>2 years) of patients with ISR undergoing repeat coronary interventions are not well established.
METHODS: The Restenosis Intrastent: Balloon angioplasty versus elective Stenting (RIBS) randomized study compared these two strategies in 450 patients with ISR. A detailed systematic protocol was used for late clinical follow-up.
RESULTS: At one-year follow-up (100% of patients), the event-free survival was similar in the two groups (77% stent implantation [ST] arm, 71% balloon angioplasty [BA] arm, log-rank p = 0.19). Additional long-term clinical follow-up (median 4.3 years, range 3 to 5 years) was obtained in 98.6% of patients. During this time 22 additional patients died (9 ST arm, 13 BA arm), 7 suffered a myocardial infarction (3 ST arm, 4 BA arm), 23 required coronary surgery (11 ST arm, 12 BA arm), and 9 underwent repeat coronary interventions (4 ST arm, 5 BA arm) (nonexclusive events). At four years the event-free survival was 69% in the ST arm and 64% in the BA arm (log-rank p = 0.21). Among the 10 prespecified variables, vessel size > or = 3 mm had a major influence on the clinical outcome at four years, with better results in the ST group (hazard ratio 0.51, 95% confidence interval 0.3 to 0.89, p = 0.016).
CONCLUSIONS: Patients with ISR undergoing repeat interventions have a significant event rate at late follow-up. Continued medical surveillance should be continued after one year. Patients with large vessels have a better outcome after repeat stenting.

Entities:  

Mesh:

Year:  2005        PMID: 16139121     DOI: 10.1016/j.jacc.2005.05.050

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  7 in total

Review 1.  Refractory In-Stent Restenosis: Improving Outcomes by Standardizing Our Approach.

Authors:  Ron Waksman; Micaela Iantorno
Journal:  Curr Cardiol Rep       Date:  2018-10-22       Impact factor: 2.931

2.  In-Stent Restenosis: Pathophysiology and Treatment.

Authors:  Patrick M Looser; Luke K Kim; Dmitriy N Feldman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02

3.  Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis.

Authors:  Inder M Singh; Steven J Filby; Fredy El Sakr; Eiran Z Gorodeski; A Michael Lincoff; Stephen G Ellis; Mehdi H Shishehbor
Journal:  Catheter Cardiovasc Interv       Date:  2010-08-01       Impact factor: 2.692

4.  A meta-analysis of randomised controlled trials assessing drug-eluting stents and vascular brachytherapy in the treatment of coronary artery in-stent restenosis.

Authors:  Lisa N Oliver; Petra G Buttner; Helen Hobson; Jonathan Golledge
Journal:  Int J Cardiol       Date:  2007-05-03       Impact factor: 4.164

5.  Circumflex artery-related acute myocardial infarction: limited ECG abnormalities but poor outcome.

Authors:  S Rasoul; M J de Boer; H Suryapranata; J C A Hoorntje; A T M Gosselink; F Zijlstra; J P Ottervanger; J H E Dambrink; A W J van 't Hof
Journal:  Neth Heart J       Date:  2007       Impact factor: 2.380

Review 6.  Diagnosis and management challenges of in-stent restenosis in coronary arteries.

Authors:  M Chadi Alraies; Fahed Darmoch; Ramyashree Tummala; Ron Waksman
Journal:  World J Cardiol       Date:  2017-08-26

7.  Mehran in-stent restenosis classification adapted for coronary bifurcations: the impact on 4-year follow-up from randomized clinical studies POLBOS I and II.

Authors:  Jacek Bil; Robert J Gil; Adam Kern; Luis A Inigo-Garcia; Radoslaw Formuszewicz; Slawomir Dobrzycki
Journal:  Postepy Kardiol Interwencyjnej       Date:  2018-09-21       Impact factor: 1.426

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.